Effects of the selective serotonin reuptake inhibitor fluoxetine on glucose metabolism: A systematic review

Bacaltchuk, 2003, Antidepressants versus placebo for people with bulimia nervosa, Cochrane Database Syst. Rev., 4 Barnard, 2013, Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review, Diabetes Care, 36, 3337, 10.2337/dc13-0560 Beyazyüz, 2013, Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study, Psychiatry Investig., 10, 148, 10.4306/pi.2013.10.2.148 Biagetti, 2013, Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes, World J. Clin. Cases, 1, 169, 10.12998/wjcc.v1.i5.169 Breum, 1995, Long-term effects of fluoxetine on glycemic control in obese patients with noninsulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity, Metabolism, 44, 1570, 10.1016/0026-0495(95)90077-2 Briscoe, 2008, Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes, Diabetes, 57, 3315, 10.2337/db08-1000 Briscoe, 2008, Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals, Diabetes, 57, 2453, 10.2337/db08-0236 Che, 2018, Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial, Neuropsychiatr. Dis. Treat., 14, 1527, 10.2147/NDT.S167608 Cipriani, 2018, Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, 391, 1357, 10.1016/S0140-6736(17)32802-7 Coleman, 2013, Depression and death in diabetes; 10-year follow-up of all-cause and cause-specific mortality in a diabetic cohort, Psychosomatics, 54, 428, 10.1016/j.psym.2013.02.015 Daubresse, 1996, Usefulness of fluoxetine in obese noninsulin-dependent diabetics: a multicenter study, Obes. Res., 4, 391, 10.1002/j.1550-8528.1996.tb00247.x Connolly, 1995, A study of fluoxetine in obese elderly patients with type 2 diabetes, Diabet. Med., 12, 416, 10.1111/j.1464-5491.1995.tb00505.x Deeg, 1996, Hypoglycemia associated with the use of fluoxetine, West J. Med., 164, 262 Dismuke, 2010, Association between major depression, depressive symptoms and personal income in US adults with diabetes, Gen. Hosp. Psychiatry, 32, 484, 10.1016/j.genhosppsych.2010.06.004 Dunbar, 2008, Depression: an important comorbidity with metabolic syndrome in a general population, Diabetes Care, 31, 2368, 10.2337/dc08-0175 Fawzi, 2016, Psychiatric referral and glycemic control of Egyptian type 2 diabetes mellitus patients with depression, Gen. Hosp. Psychiatry, 40, 60, 10.1016/j.genhosppsych.2016.01.002 Ghaeli, 2004, Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder, J. Clin. Psychopharmacol., 24, 386, 10.1097/01.jcp.0000132441.27854.0d Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care, 27, 1761, 10.2337/diacare.27.7.1761 Goldstein, 1995, Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success, Obes. Res., 4, 481, 10.1002/j.1550-8528.1995.tb00216.x Gonzalez, 2007, Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity, Diabetes Care, 30, 2222, 10.2337/dc07-0158 Goodnick, 2001, Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy, Ann. Clin. Psychiatry, 13, 31, 10.3109/10401230109147127 Gray, 1992, Fluoxetine treatment of the obese diabetic, Int. J. Obes. Relat. Metab. Disord., 16, 193 Guimarães, 2006, Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients, Arq. Bras. Endocrinol. Metab., 50, 1020, 10.1590/S0004-27302006000600007 Gulseren, 2005, Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients, Arch. Med. Res., 36, 159, 10.1016/j.arcmed.2004.12.018 Kaye, 1998, Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa, Biol. Psychiatry, 44, 825, 10.1016/S0006-3223(98)00195-4 Khazaie, 2011, Treatment of depression in type 2 diabetes with fluoxetine or citalopram?, Neurosciences, 16, 42 Lear, 1992, Fluoxetine side-effects mimicking hypoglycemia, Lancet, 339, 1296, 10.1016/0140-6736(92)91624-H Lustman, 2000, Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial, Diabetes Care, 23, 618, 10.2337/diacare.23.5.618 Maheux, 1997, Fluoxetine improves insulin sensitivity in obese patients with noninsulin-dependent diabetes mellitus independent of weight loss, Int. J. Obes. Relat. Metab. Disord., 21, 97, 10.1038/sj.ijo.0800372 Magni, 2013, Fluoxetine versus other types of pharmacotherapy for depression, Cochrane Database Syst. Rev., 17 Moosa, 2003, African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion, J. Clin. Psychopharmacol., 23, 549, 10.1097/01.jcp.0000095341.32154.8f O’Kane, 1994, Fluoxetine in the treatment of obese type 2 diabetic patients, Diabet. Med., 11, 105, 10.1111/j.1464-5491.1994.tb00238.x Park, 2002, Does fluoxetine administration influence insulin resistance in 90% pancreatectomized rats?, Metabolism, 51, 38, 10.1053/meta.2002.26712 Parto, 2017, Obesity and cardiovascular diseases, Curr. Probl. Cardiol., 42, 376, 10.1016/j.cpcardiol.2017.04.004 Rao, 2020, Obesity increases the risk of depression in children and adolescents: Results from a systematic review and meta-analysis, J. Affect Disord., 267, 78, 10.1016/j.jad.2020.01.154 Roopan, 2017, Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review, Acta Neuropsychiatr., 29, 127, 10.1017/neu.2016.54 Roy, 2012, Epidemiology of depression and diabetes: a systematic review, J. Affect Disord., 142, S8, 10.1016/S0165-0327(12)70004-6 Sartorius, 2018, Depression and diabetes, Dialog-. Clin. Neurosci., 20, 47, 10.31887/DCNS.2018.20.1/nsartorius Sawka, 2000, Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride, J. Pediatr., 136, 394, 10.1067/mpd.2000.103851 Serralde-Zúñiga, 2019, Fluoxetine for adults who are overweight or obese, Cochrane Database Syst. Rev., 10 Shahsavand Ananloo, 2013, Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression, Daru, 21, 4, 10.1186/2008-2231-21-4 Sohel, 2021, Fluoxetine, 2021 Suplicy, 2014, A comparative study of five centrally acting drugs on the pharmacological treatment of obesity, Int. J. Obes., 38, 1097, 10.1038/ijo.2013.225 Stapel, 2019, Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells, Expert Opin. Ther. Targets, 23, 883, 10.1080/14728222.2019.1675639 Tharmaraja, 2019, The association between selective serotonin reuptake inhibitors and glycemia: a systematic review and meta-analysis of randomized controlled trials, Psychosom. Med., 81, 570, 10.1097/PSY.0000000000000707 Visser, 1994, No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, andor blood pressure in healthy men with abdominal obesity, Obes. Res., 2, 152, 10.1002/j.1550-8528.1994.tb00641.x Watanabe, 2011, Role of peripheral serotonin in glucose and lipid metabolism, Curr. Opin. Lipido, 22, 186, 10.1097/MOL.0b013e3283462273 Yamada, 1999, SelectiveThe selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms, Eur. J. Pharmacol., 382, 211, 10.1016/S0014-2999(99)00593-2 Ye, 2011, Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials, PLoS One, 6, 10.1371/journal.pone.0021551